Novartis Institutes for BioMedical Research (NIBR) is Novartis’ global research organization. Informed by clinical insights from our translational medicine team, we are using modern science and technology to discover new medicines for patients worldwide.
 

With talented scientists located in eight Institutes around the world, we are committed to leveraging knowledge we gain from our innovative research and discoveries made at leading academic institutions and biotechnology companies.
 

Over the past several years, Novartis has had the greatest number of new molecular entities approved by the FDA for clinical use in the  US. With our ongoing focus on diseases with unmet medical needs, NIBR scientists ensure that Novartis maintains its robust pipeline and successful track record in innovative drug discovery.
 

NIBR is headed by Prof. Mark Fishman and headquartered in Cambridge, Massachusetts, USA with a major research facility in Basel, Switzerland. Other key research sites are located in Horsham, United Kingdom; Vienna, Austria; Tsukuba, Japan; East Hanover, New-Jersey, USA and Shanghai, China.